ABSTRACT

Introduction

Obesity is a major public health concern with an increasing prevalence. Recent studies suggest an influence of gastrointestinal microbiota on obesity. Consequently, microbiota restoration therapies are being considered as potential management. We present data on microbiome markers and the future of microbiota therapeutics for obesity.

Areas Covered

We summarize the pathogenesis of obesity, relationship between gut microbiota and obesity, use of microbiota-based therapies. Data were gathered by a literature search of articles in PubMed from the date of inception till August 2020. Keywords used were ‘gut microbiota,’ ‘gut microbiome,’ ‘microbiota,’ ‘microbiome,’ ‘obesity,’ and ‘obesity and fecal microbiota transplantation’ as MeSH terms.

Expert Opinion

The direct relationship of gut microbiota in causing obesity needs exploration. Because of the scarcity of human studies, the utility of microbiota-based therapies as treatment remains uncertain and the use of microbiome restoration for obesity should be restricted to research settings. To evaluate the efficacy of microbiota restoration, studies using these therapies as an adjunct with diet and lifestyle should be conducted. Once relationships between bacterial strains and the human metabolic profile are determined, these strains could be cultured for transfer to obese patients. Such advancement could help in tailoring personalized therapies for obese persons.

中文翻译：

---

肠道菌群：干预肥胖的目标

摘要

介绍

肥胖是一个主要的公共卫生问题，其患病率正在上升。最近的研究表明，胃肠道微生物群对肥胖有影响。因此，微生物群修复疗法被认为是潜在的管理方法。我们提供了有关微生物组标志物的数据以及肥胖微生物群疗法的未来。

涵盖的领域

我们总结了肥胖的发病机制、肠道微生物群与肥胖之间的关系、基于微生物群的疗法的使用。数据是通过在 PubMed 中从成立之日到 2020 年 8 月的文章的文献检索收集的。使用的关键词是“肠道微生物群”、“肠道微生物群”、“微生物群”、“微生物群”、“肥胖”和“肥胖和粪便”微生物群移植”作为 MeSH 术语。

专家意见

肠道微生物群与肥胖的直接关系需要探索。由于人类研究的稀缺性，基于微生物群的疗法作为治疗的效用仍然不确定，并且微生物组恢复对肥胖的使用应仅限于研究环境。为了评估微生物群恢复的功效，应进行使用这些疗法作为饮食和生活方式的辅助手段的研究。一旦确定了细菌菌株与人体代谢谱之间的关系，就可以培养这些菌株以转移给肥胖患者。这种进步可能有助于为肥胖者量身定制个性化疗法。